NAMS

Analyst Note: NewAmsterdam Pharma Company N.V. (NAMS)

Date: 2026-06-13 Current Price: $29.83

1. Structural Readiness

Conservative Entry: Not yet triggered (awaiting confirmed breakout). Breakout Level: Unconfirmed. The market is currently testing the upper boundary of the consolidation range. Extension: Not applicable (price is within the coil structure, not extended above it). ATR Context: Current ATR is 6.1% (Very High). This elevated volatility suggests significant price movement is possible in either direction as the market digests the upcoming regulatory decisions.

2. Thesis Layer

Primary Secular Thesis: Biotech & GLP-1 → GLP-1 / Metabolic (Tier Direct). Company Role: NewAmsterdam Pharma is a direct beneficiary of the metabolic disease treatment wave, specifically through its lead asset, obicetrapib. While the company is not a GLP-1 agonist developer, it operates in the adjacent and highly correlated "Metabolic" tier, targeting the same patient population (ASCVD and hypercholesterolemia) with a novel mechanism (cholesterol ester transfer protein inhibitor). Exposure Weighting: The company is a pure-play on the cholesterol-lowering therapeutic class. The "Biotech & GLP-1" classification reflects the high conviction in the metabolic sector's growth trajectory. The directness of the exposure is high, as obicetrapib is positioned to address a massive unmet need in patients who cannot tolerate or fail to reach goals with statins alone.

3. Business Overview

Business Model: NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on the development of obicetrapib, a potent oral cholesterol ester transfer protein (CETP) inhibitor. The company's business model relies on advancing clinical trials to regulatory approval and subsequently commercializing the asset, either independently or via a partnership. Industry: Healthcare / Biotechnology / Lipid Metabolism. Supporting Evidence (As of 2026-06-13):

• Clinical Success: The company has successfully completed Phase 3 trials (BROADWAY, TANDEM, and BROOKLYN). Data shows obicetrapib 10 mg monotherapy reduced LDL-C by 33% (BROADWAY) and 36% (BROOKLYN) compared to placebo. The Fixed-Dose Combination (FDC) of obicetrapib plus ezetimibe (TANDEM) demonstrated a 52% mean LDL-C reduction.
• Regulatory Status: As of August 2025, the EMA accepted Marketing Authorization Applications (MAAs) for obicetrapib monotherapy and the FDC. Management expects regulatory decisions on these MAAs in the second half of 2026.
• Commercialization Plan: If approved, Menarini (the commercial partner) is expected to launch the product in Germany and the UK in the fourth quarter of 2026.
• Pipeline: Enrollment for the cardiovascular outcomes trial (PREVAIL) was completed in April 2024. The company expects the Data Safety Monitoring Board (DSMB) recommendation based on interim analysis in Q1 2027.
• Market Opportunity: Management estimates 30 million patients in the U.S. are not at LDL-C goals despite therapy, with 13 million having ASCVD.

4. Archetype and Conviction

Archetype: Growth Leader. Fit Analysis: The company fits the "Growth Leader" archetype due to the successful completion of pivotal Phase 3 trials and the imminent transition from clinical development to commercialization. The "Growth" narrative is driven by the potential for rapid revenue generation upon the anticipated H2 2026 regulatory approvals and Q4 2026 launches. Conviction Stack:

• Thesis Strength: High. The metabolic disease sector is a dominant secular theme, and obicetrapib addresses a clear, high-volume unmet need.
• Evidence Quality: Strong. The evidence base (E1-E16) confirms successful Phase 3 topline results and a clear regulatory pathway.
• Rerating Potential: Significant. The market is currently pricing in the binary risk of regulatory approval. A successful decision in H2 2026 would likely trigger a re-rating from a clinical-stage valuation to a commercial-stage valuation.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Confirmation of regulatory approval from the EMA or FDA in the second half of 2026.
• Positive DSMB recommendation from the PREVAIL trial in Q1 2027.
• Successful commercial launch in Germany/UK in Q4 2026 with strong uptake.

What Would Invalidate the Case:

• A regulatory rejection or significant delay of the MAAs beyond the second half of 2026.
• Negative safety signals emerging from the PREVAIL trial or post-approval data.

Gaps in Evidence Base:

• Financial Runway: While clinical progress is detailed, specific data on cash burn rates or the exact timing of the next capital raise (if needed) prior to commercialization is not explicitly detailed in the provided evidence snippets.
• Competitive Landscape: While the market size is defined, specific competitive dynamics against newer GLP-1 agents or other lipid therapies are not quantified in the provided text.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Successful completion of Phase 3 BROADWAY, TANDEM, and BROOKLYL trials with robust LDL-C reduction data; EMA acceptance of MAAs in August 2025; clear management timeline for regulatory decisions in H2 2026 and potential Q4 2026 launch. Sizing hint: Position size should be reduced relative to a confirmed breakout due to the "forming" state and binary regulatory risk; treat as a partial position pending confirmation. Expected path: Price likely consolidates near current levels as the market awaits H2 2026 regulatory decisions; a breakout above the coil resistance would signal confirmation of the commercialization thesis. Expected horizon: 6 to 12 months (aligned with the H2 2026 regulatory decision window).